Rafael Holdings, Inc. (NYSE:RFL) Sees Large Decline in Short Interest

Rafael Holdings, Inc. (NYSE:RFL) was the recipient of a significant decline in short interest in March. As of March 13th, there was short interest totaling 40,019 shares, a decline of 27.5% from the February 26th total of 55,181 shares. Approximately 0.1% of the company’s stock are short sold. Based on an average daily volume of 161,646 shares, the short-interest ratio is presently 0.2 days.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Rafael in a report on Monday, December 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Rafael has a consensus rating of “Sell”.

Rafael Stock Down 0.8%

NYSE RFL traded down $0.01 during trading hours on Friday, hitting $1.25. 39,529 shares of the company were exchanged, compared to its average volume of 111,500. The firm has a market cap of $65.01 million, a price-to-earnings ratio of -1.58 and a beta of 0.58. The company has a 50 day moving average of $1.28 and a two-hundred day moving average of $1.30. Rafael has a 52-week low of $1.12 and a 52-week high of $3.19.

Rafael (NYSE:RFL) last announced its quarterly earnings data on Monday, March 16th. The company reported ($0.13) earnings per share (EPS) for the quarter. Rafael had a negative net margin of 2,846.60% and a negative return on equity of 37.27%. The company had revenue of $0.21 million during the quarter.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in RFL. Geode Capital Management LLC raised its holdings in shares of Rafael by 72.9% in the 2nd quarter. Geode Capital Management LLC now owns 451,139 shares of the company’s stock valued at $781,000 after purchasing an additional 190,179 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Rafael during the second quarter worth $50,000. Cable Car Capital LP purchased a new position in Rafael in the second quarter valued at $173,000. Vanguard Group Inc. increased its holdings in Rafael by 10.5% in the third quarter. Vanguard Group Inc. now owns 1,394,726 shares of the company’s stock valued at $1,897,000 after buying an additional 133,024 shares during the last quarter. Finally, Citadel Advisors LLC raised its stake in Rafael by 132.3% in the third quarter. Citadel Advisors LLC now owns 72,584 shares of the company’s stock valued at $99,000 after buying an additional 41,335 shares in the last quarter. Institutional investors and hedge funds own 11.30% of the company’s stock.

Rafael Company Profile

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.